Fingolimod is the first oral disease-modifying drug approved for the treatment of multiple sclerosis. The drug is usually well-tolerated, and common side effects include bradycardia, headache, flu, diarrhea, back pain, increased liver enzymes and cough. Fingolimod is thought to provide therapeutic benefit by preventing normal lymphocyte egress from lymphoid tissues, thus reducing the infiltration of autoaggressive lymphocytes into the central nervous system. However, the drug modulates sphingosine-1-phosphate (S1P) receptors and induces several biological responses, by influencing endothelial cell–cell adhesion, angiogenesis, vascular development, and cardiovascular function.
Does Fingolimod induce peripheral vascular side effects? A case study
GUARNERI, ClaudioPrimo
;RUSSO, MARGHERITA;MAZZON, EMANUELA;Serafinella, Patrizia Cannavò;BRAMANTI, Placido;CALABRO', ROCCO SALVATOREUltimo
2016-01-01
Abstract
Fingolimod is the first oral disease-modifying drug approved for the treatment of multiple sclerosis. The drug is usually well-tolerated, and common side effects include bradycardia, headache, flu, diarrhea, back pain, increased liver enzymes and cough. Fingolimod is thought to provide therapeutic benefit by preventing normal lymphocyte egress from lymphoid tissues, thus reducing the infiltration of autoaggressive lymphocytes into the central nervous system. However, the drug modulates sphingosine-1-phosphate (S1P) receptors and induces several biological responses, by influencing endothelial cell–cell adhesion, angiogenesis, vascular development, and cardiovascular function.File | Dimensione | Formato | |
---|---|---|---|
AAD meeting 2016.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
45.06 kB
Formato
Adobe PDF
|
45.06 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.